Ko Hyeonseok, Kim Young-Joo, Park Jin-Soo, Park Jeong Hill, Yang Hyun Ok
Natural Products Research Center, Korea Institute of Science and Technology, Gangwon-do, Korea.
Biosci Biotechnol Biochem. 2009 Oct;73(10):2183-9. doi: 10.1271/bbb.90250. Epub 2009 Oct 7.
Our previous study indicated that ginsenoside Rk1 has anti-tumor activity and that its mode of action in HepG2 cells treated for 48 h involves coordinated inhibition of telomerase and induction of apoptosis. In the present study, we found that Rk1 induces both G(1) phase arrest and autophagy, but not apoptosis, at an earlier stage of treatment. A 24-h incubation of HepG2cells with Rk1 induced G(1) phase arrest. Rk1-induced autophagy was documented by the conversion of microtubule associated protein light chain 3 (LC3)-I to LC3-II, an autophagosome marker, and monodansylcadaverine (MDC) incorporation into autolysosomes. Combination of Rk1 with an autophagy inhibitor, such as bafilomycin A1 or beclin 1 siRNA, enhanced the anti-tumor effect of Rk1. These results imply that autophagy functions as a survival mechanism in HepG2 cells against Rk1-induced apoptosis. Taken together, our results support the use of autophagy inhibitors in combination with Rk1 as an effective anti-cancer regimen in HepG2 cells.
我们之前的研究表明,人参皂苷Rk1具有抗肿瘤活性,其在处理48小时的HepG2细胞中的作用模式涉及对端粒酶的协同抑制和凋亡诱导。在本研究中,我们发现Rk1在处理的早期阶段诱导G(1)期阻滞和自噬,但不诱导凋亡。用Rk1对HepG2细胞进行24小时孵育可诱导G(1)期阻滞。Rk1诱导的自噬通过微管相关蛋白轻链3(LC3)-I向自噬体标志物LC3-II的转化以及单丹磺酰尸胺(MDC)掺入自溶酶体来记录。Rk1与自噬抑制剂(如巴弗洛霉素A1或贝clin 1 siRNA)联合使用可增强Rk1的抗肿瘤作用。这些结果表明,自噬在HepG2细胞中作为一种对抗Rk1诱导的凋亡的存活机制发挥作用。综上所述,我们的结果支持将自噬抑制剂与Rk1联合使用作为HepG2细胞中一种有效的抗癌方案。